Modernatx, Inc.

Jennifer Nelson

Edward John Miracco

Gabor Butora

Stephen G Hoge

William Joseph Issa

Matthew G Stanton

Andrew W Fraley

Amy E Rabideau

Amy Rhoden Smith

John Reynders

Brian R Fritz

Amy Rhoden-smith

William Issa

John Van Wicheren Iii Reynders

The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.

High purity RNA compositions and methods for preparation thereof

The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by inproved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.

The invention features polynucleotides encoding a polypeptide including a 3'-stabilizing region and having increased stability compared to wild-type polynucleotides.

Polynucleotides containing a stabilizing tail region

The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.

Polynucleotides containing a morpholino linker

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of circular polynucleotides.

Circular polynucleotides

The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

Growing community of inventors

Brookline, MA, United States of America

Jennifer Nelson